← Leaderboards
Catherine Elizabeth Oldenburg
University Of California, San Francisco
$6,320,431
Attributed
$9,935,190
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,935,190 · 7
By mechanism
UG1$7,229,518 · 2
R01$1,858,447 · 2
R21$847,225 · 3
Top collaborators
- Thomas M Lietman13 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Jenny Xin Liu$6,160,625
- Jeremy David Keenan$19,787,326
- Moses Robert Kamya$27,245,027
- Diane V Havlir$125,216,731
- Philip Rosenthal$4,268,588
Others in their field
Other Emerging Leaders on “Child”
- April Brinkoetter · Hungry Heart Media, Inc.$57,302,265
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$29,616,650
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$28,898,304
- Ellen Gould Chadwick · Harvard University D/B/A Harvard School Of Public Health$25,473,113
- Beth Baseler · Leidos Biomedical Research, Inc.$22,470,677
- Gaurav J Dave · Duke University$17,082,764
Research focus
ChildAntibioticsProgramsRandomizedAzithromycinAreaWorld Health OrganizationInfectionCommunitiesPrevalenceTrachomaPopulation BasedGuidelinesLow PrevalenceChlamydia TrachomatisCountryPublic HealthRandomized Placebo Controlled TrialTransmission ProcessLeadChlamydiaAgedMexicoGambia
Grant awards (21)
Azithromycin as adjunctive treatment for uncomplicated severe acute malnutrition: the AMOUR trial$619,411
R01 · FY2025 · HD · contact PI
Vitality in Infants Via Azithromycin for Neonates Trial (VIVANT)$450,170
R01 · FY2025 · HD · contact PI
Understanding the role of caregiver mental health in outcomes following childhood severe acute malnutrition$237,765
R21 · FY2025 · MH · contact PI
Leveraging the seasonal malaria chemoprevention platform to address malaria and malnutrition$214,160
R21 · FY2025 · AI · contact PI
Vitality in Infants Via Azithromycin for Neonates Trial (VIVANT)$166,724
R01 · FY2025 · HD · contact PI
Azithromycin Reduction to Reach Elimination of Trachoma$837,133
UG1 · FY2024 · EY · contact PI
Azithromycin as adjunctive treatment for uncomplicated severe acute malnutrition: the AMOUR trial$622,142
R01 · FY2024 · HD · contact PI
Azithromycin Reduction to Reach Elimination of Trachoma$793,062
UG1 · FY2023 · EY · contact PI
Azithromycin Reduction to Reach Elimination of Trachoma$26,005
UG1 · FY2023 · EY · contact PI
Kebele Elimination of Trachoma for Ocular Health$842,897
UG1 · FY2022 · EY · contact PI
Azithromycin Reduction to Reach Elimination of Trachoma$766,312
UG1 · FY2022 · EY · contact PI
Azithromycin Reduction to Reach Elimination of Trachoma$73,360
UG1 · FY2022 · EY · contact PI
Azithromycin Reduction to Reach Elimination of Trachoma$766,312
UG1 · FY2021 · EY · contact PI
Kebele Elimination of Trachoma for Ocular Health$626,247
UG1 · FY2021 · EY · contact PI
Azithromycin in the Outpatient Management of Severe Acute Malnutrition$210,150
R21 · FY2021 · HD · contact PI
Azithromycin Reduction to Reach Elimination of Trachoma$50,816
UG1 · FY2021 · EY · contact PI
Azithromycin Reduction to Reach Elimination of Trachoma$813,579
UG1 · FY2020 · EY · contact PI
Azithromycin in the Outpatient Management of Severe Acute Malnutrition$185,150
R21 · FY2020 · HD · contact PI
Kebele Elimination of Trachoma for Ocular Health$605,504
UG1 · FY2019 · EY · contact PI
Kebele Elimination of Trachoma for Ocular Health$587,022
UG1 · FY2018 · EY · contact PI
Kebele Elimination of Trachoma for Ocular Health$441,269
UG1 · FY2017 · EY · contact PI